BN 80927: structure in first source [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]
| ID Source | ID |
|---|---|
| PubMed CID | 216300 |
| MeSH ID | M0336745 |
| Synonym |
|---|
| 220997-99-9 |
| bn 80927 |
| unii-5wm1f45i4y |
| bn-80927 |
| 3h,15h-oxepino(3',4':6,7)indolizino(1,2-b)quinoline-3,15-dione, 9-chloro-5-ethyl-1,4,5,13-tetrahydro-5-hydroxy-10-methyl-12-((4-methyl-1-piperidinyl)methyl)-, monohydrochloride, (5r)- |
| 5wm1f45i4y , |
| 3h,15h-oxepino[3',4':6,7]indolizino[1,2-b]quinoline-3,15-dione,9-chloro-5-ethyl-1,4,5,13-tetrahydro-5-hydroxy-10-methyl-12-[(4-methyl-1-piperidinyl)methyl]-,hydrochloride (1:1), (5r)- |
| elomotecan hydrochloride |
| bn80927 |
| elomotecan (hydrochloride) |
| DTXSID60944734 |
| 9-chloro-5-ethyl-5-hydroxy-10-methyl-12-[(4-methylpiperidin-1-yl)methyl]-1,4,5,13-tetrahydro-3h,15h-oxepino[3',4':6,7]indolizino[1,2-b]quinoline-3,15-dione--hydrogen chloride (1/1) |
| (20r)-6-chloro-20-ethyl-20-hydroxy-7-methyl-10-[(4-methylpiperidin-1-yl)methyl]-17-oxa-3,13-diazapentacyclo[11.9.0.02,11.04,9.015,21]docosa-1(22),2,4(9),5,7,10,15(21)-heptaene-14,18-dione;hydrochloride |
| Q27262966 |
| CS-0007488 |
| HY-13622 |
| AKOS040757408 |
| (r)-9-chloro-5-ethyl-5-hydroxy-10-methyl-12-((4-methylpiperidin-1-yl)methyl)-4,5-dihydrooxepino[3',4':6,7]indolizino[1,2-b]quinoline-3,15(1h,13h)-dione hydrochloride |
| Excerpt | Reference | Relevance |
|---|---|---|
| " Plasma concentration data and adverse effects were modeled using the population approach." | ( Population pharmacokinetic/pharmacodynamic modeling of drug-induced adverse effects of a novel homocamptothecin analog, elomotecan (BN80927), in a Phase I dose finding study in patients with advanced solid tumors. Cendrós, JM; Cvitkovic, F; Delavault, P; Lesimple, T; Obach, R; Peraire, C; Perez-Mayoral, A; Principe, P; Pruñonosa, J; Soto, E; Trocóniz, IF, 2012) | 0.38 |
| Timeframe | Studies, This Drug (%) | All Drugs % |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 1 (16.67) | 18.2507 |
| 2000's | 4 (66.67) | 29.6817 |
| 2010's | 1 (16.67) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| [information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||
According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be weak demand-to-supply ratio for research on this compound.
| This Compound (12.23) All Compounds (24.57) |
| Publication Type | This drug (%) | All Drugs (%) |
|---|---|---|
| Trials | 1 (16.67%) | 5.53% |
| Reviews | 1 (16.67%) | 6.00% |
| Case Studies | 0 (0.00%) | 4.05% |
| Observational | 0 (0.00%) | 0.25% |
| Other | 4 (66.67%) | 84.16% |
| [information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||